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Abstract
Background: Medulloblastomas (MBs) and supratentorial primitive neuroectodermal tumours (PNETs) are the most 
common highly aggressive paediatric brain tumours. In spite of extensive research on these tumours, there are only 
few known biomarkers or therapeutic target proteins, and the prognosis of patients with these tumours remains poor. 
Our aim was to investigate whether carbonic anhydrases (CAs), enzymes commonly overexpressed in various tumours 
including glioblastomas and oligodendrogliomas, are present in MBs and PNETs, and whether their expression can be 
correlated with patient prognosis.
Methods: We determined the expression of the tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a 
series of MB/PNET specimens (n = 39) using immunohistochemistry.
Results: Endothelial CA II, cytoplasmic CA II, CA IX and CA XII were expressed in 49%, 73%, 23% and 11% of the 
tumours, respectively. CA II was detected in the neovessel endothelium and the tumour cell cytoplasm. CA IX was 
mainly expressed in the tumour cells located in perinecrotic areas. CA XII showed the most homogenous distribution 
within the tumours. Importantly, CA IX expression predicted poor prognosis in both univariate (p = 0.041) and 
multivariate analyses (p = 0.016).
Conclusions: We suggest that CA IX should be considered a potential prognostic and therapeutic target in MBs and 
PNETs.
Background
Medulloblastomas (MBs) and primitive neuroectodermal
tumours (PNETs) are classified as embryonal tumours of
the central nervous system (CNS) and histologically cor-
respond to WHO grade IV [1]. One viewpoint postulates
that these tumours show a common ontogeny, arising
from related progenitor cells that have the potential for
divergent neuroepithelial differentation. However, in
recent years molecular genetic analyses have demon-
strated different genetic profiles for these tumours [1]. It
has been proposed that MBs originate from the neoplas-
tic transformation of granule cell precursors in the cere-
bellum via deregulation of molecular pathways involved
in normal cerebellar development [2,3]. Correspondingly,
PNETs arise in the cerebral hemispheres, brain stem or
spinal cord. The neuroepithelial tumour cells of a PNET
may be undifferentiated or poorly differentiated. In addi-
tion, the tumour cells may have aberrant differentiations,
including neuronal, astrocytic and ependymal lines.
MB is the most common childhood malignant tumour
of the central nervous system and accounts for 12-25% of
all paediatric CNS tumours. It is very rare in adults,
accounting for only 0.5-1% of brain tumours [4]. The
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main defective cell signalling pathways involved in the
development of MB include the Hedgehog and Wnt path-
ways, but the exact molecular mechanisms contributing
to tumourigenesis in both MB and PNET are still poorly
understood [5].
MBs are sensitive to chemotherapy and radiation, but
surgical resection continues to be the most effective
treatment [6,7]. Patients with PNET undergo a similar
treatment process to patients with MB [8]. There has
been a marked improvement in the 5-year survival rate in
MB patients, as the survival percentage has improved
from 2-30% in the 1970s to 60-70% currently [1,4]. Unfor-
tunately, the current clinical staging does not effectively
identify the patients whose tumours will be resistant to
chemotherapy and radiation. To individualise therapies
and minimise side-effects of aggressive treatments, we
need to overcome the major challenge of identifying the
high- and low-risk patients. While the prognosis for
patients with MB has improved, children with PNET have
an even worse prognosis than patients with MB. Cur-
rently, the 5-year survival rate for patients with PNET is
24-38% [9,10].
The carbonic anhydrases (CAs) are zinc-containing
metalloenzymes that catalyse the reversible hydration of
carbon dioxide (CO2 + H2O ? HCO3
- + H+), and, thus,
participate in the maintenance of pH homeostasis in the
body [11-14]. The mammalian α-CA gene family encodes
at least thirteen enzymatically active isoforms with differ-
ent structural and catalytic properties, and twelve of
these are expressed in human tissues [15]. CA isozymes
II, IX and XII have been associated with neoplastic pro-
cesses, and they are potential histological and prognostic
biomarkers of certain tumours, including diffuse astrocy-
tomas [12,16,17]. CA II is the most widely distributed
member of the CA gene family, being present in virtually
every human tissue and organ. It is catalytically one of the
most efficient enzymes known [18]. It is present to some
extent in malignant cells, and, interestingly, it has been
recently shown to be ectopically expressed in the
endothelial cells of tumour neovessels [17,19]. Trans-
membrane enzyme, CA IX, was first recognised as a
novel tumour-associated antigen expressed in several
types of human carcinomas as well as in normal gastroin-
testinal tissue [12,20,21]. It has been functionally linked
to cell adhesion, differentiation, proliferation and onco-
genic processes [12,22], and its enzymatic activity is com-
parable to CA II [23]. Another transmembrane CA
isozyme, CA XII, was first found in normal kidney tissue
and renal cell carcinoma [24,25]. Later studies have
shown that it is expressed in several other tumours, but
also in some normal organs such as the colon and uterus
[26,27].
CA IX and XII seem to be regulated by similar mecha-
nisms, as transcription of these isozymes is induced in
tumours under hypoxic conditions through hypoxia
inducible factor-1 alpha (HIF-1α)-mediated pathways
[28]. Even though very little is known about the regula-
t i o n  o f  C A  I I  e x p r e s s i o n ,  i t  i s  u n l i k e l y  t h a t  H I F - 1 α  i s
involved. High expression of CA II, IX and XII in certain
tumours, such as astrocytomas and oligodendrogliomas
[16,17,29,30], has suggested that these enzymes may
functionally participate in the invasion process, which is
facilitated by acidification of the extracellular space [31].
In favour of this hypothesis, it has been shown in vitro
that CA inhibitors can reduce the invasion capacity and
proliferation of cancer cells [32-34].
To our knowledge, this is the first study to assess the
expression of tumour-associated CAs in MBs and PNETs.
Here we evaluate the expression of CA II, IX and XII in
association with the patient age, survival and molecular
pathologic features such as apoptosis and expression of c-
erbB2, MIB-1 and bcl-2.
Methods
Study material
Brain tumour samples were obtained from 35 patients (15
females and 20 males) with either MBs or supratentorial
PNETs who were operated on at the University Hospitals
of Tampere and Turku, Finland, from1989-2005. The
term supratentorial PNET is used as a synonym for CNS
PNET, not otherwise specified [1]. MBs were observed in
28 patients and supratentorial PNETs in 7 patients. In
addition, there were four patients with a recurrent
tumour (two MBs: recurrence after 8 and 29 months in
the cerebellum; two supratentorial PNETs: recurrences
after 9 and 71 months in the brain stem and left frontal
lobe, respectively). Taken together, our material included
39 surgical tumour samples. The age of the patients var-
ied from newborn to 68 years (median = 7.4, mean ± SD =
14.4 ± 17.2), Table 1.
In the early nineties eight-drugs-in-one -protocol and
later vincristine, lomustine and prednisolon were widely
used also for MB and PNETs [35]. Later the treatment in
older children (over three years of age) started with radia-
tion therapy with weekly vincristin doses (craniospinal
dose 36 Gy and total tumor dose 54-55 Gy), and after
irradiation a chemotherapy protocol using cisplatin,
CCNU and vincristine was applied [36]. The later proto-
col is still in use. Children under three years of age have
been treated with multidrug chemotherapy protocols
from Childrens Cancer Group (USA) or German HIT-
SKK-group generally without radiation therapy. Of the 35
patients, 4 received preoperative chemotherapy and/or
radiation therapy, and these four patients all had a recur-
rent tumour. The tumours were radically resected if pos-
sible, and most patients were also treated with
postoperative chemo- and/or radiotherapy as follows:
three patients received surgery only, five patients wereNordfors et al. BMC Cancer 2010, 10:148
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post-operatively treated with chemotherapy, four under-
went radiotherapy and twenty-three patients received
both postoperative chemotherapy and radiotherapy,
Table 1.
The overall survival was known for 35 patients, and 17
patients were alive and 18 patients dead at the end of the
follow-up period. The 5-year survival for our patients was
46% in the total tumour material, 39% in MBs and 71% in
PNETs.
All the material was gathered from surgical operations.
For immunohistochemistry, the brain tumour specimens
were fixed immediately in 4% phosphate-buffered formal-
dehyde and processed into paraffin blocks. Haematoxylin
and eosin-stained slides of the tumours were evaluated by
two experienced neuropathologists, and the histopatho-
logical typing and grading were carried out according to
WHO criteria [1]. Following the typing and grading of the
specimens, a neuropathologist (HH) pinpointed one his-
tologically representative area from each tumour with a
high cellular proliferation index (as assessed by Ki-67
(MIB-1) staining) [37], and this area was then inserted
into a multitissue block. The blocks were constructed
w i t h  a  c u s t o m - b u i l t  i n s t r u m e n t  ( B e e c h e r  I n s t r u m e n t s ,
Silver Spring, MD) and the diameter of the tissue cores
was 2 mm.
Immunohistochemistry
The monoclonal antibody M75, recognising the N-termi-
nal domain of human CA IX, has been described previ-
ously [20,21]. The rabbit anti-human CA XII antiserum
against the secretory form of CA XII has been character-
ised by Karhumaa et al. [27]. Rabbit antiserum against
human CA II has also been produced and characterised
previously [38]. Normal rabbit serum (NRS) was used for
control staining.
Immunohistochemical staining for CA II, CA IX and
CA XII were performed using an automated immunos-
taining system with the Power Vision+ Poly-HRP IHC Kit
reagents (ImmunoVision Technologies, Burlingame, CA).
Briefly, the sections were: (a) rinsed in a wash buffer; (b)
treated with 3% H2O2 in ddH2O for 5 min and rinsed in a
wash buffer; (c) blocked with the Universal IHC Block-
ing/Diluent for 30 min and rinsed in a wash buffer; (d)
incubated for 30 min with the rabbit anti-human CA II
serum, rabbit-anti human CA XII serum, monoclonal
M75 antibody or NRS diluted 1:2000 (rabbit sera) or
1:1000 (M75) in Universal IHC Blocking/Diluent; (e)
rinsed in a wash buffer for 5 min three times; (f) incu-
bated in Poly-HRP-conjugated anti-rabbit/mouse IgG for
30 min and rinsed in a wash buffer for 5 min three times;
(g) incubated in a DAB (3,3' diaminobenzidine tetrahy-
drochloride) solution (one drop DAB solution A and one
drop DAB solution B with 1 ml ddH2O) for 6 min; (h)
rinsed with ddH2O; (i) treated with CuSO4 for 5 min to
enhance the signal and (j) rinsed with ddH2O. All proce-
dures were carried out at room temperature. The sections
were finally examined and photographed with a Zeiss
Axioskop 40 microscope (Carl Zeiss; Göttingen, Ger-
many).
The staining reactivities for CA II, CA IX and CA XII
were scored from the multitissue- blocks on a scale from
0 to 3 as follows: 0, no reaction; 1, weak reaction (< 10%
positive cells); 2, moderate reaction (10-30% positive
cells); 3, strong reaction (>30% positive cells). Due to the
sample size, the staining results were categorised into two
groups: negative staining was considered as CA-negative
and weak, moderate and strong staining were considered
as CA-positive.
Table 1: Patient characteristics in different tumour subtypes and the correlation between them.
MB PNET All primary tumours p-value
Age (mean, years) 15.0 ± 17.3 11.9 ± 17.8 14.4 ± 17.2 0.343*
Sex
Females 10 5 15
Male 18 2 20 0.088**
Therapy
Surgery only 3 2 3
Surgery +radiation 3 1 4
Surgery+chemotherapy 3 0 5
Surgery+radiation+chemo 19 4 23 0.540**
* Mann-Whitney test
** chi-square testNordfors et al. BMC Cancer 2010, 10:148
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The section preparation, immunostaining and analysis
of apoptosis (TUNEL-labelling) [39] and the expression
of c-erbB-2, p53 [40] and bcl-2 [41] were done as previ-
ously described.
Statistical analysis
All statistical analyses were performed using SPSS 15.0
for Windows (Chicago, IL). The significance of the asso-
ciations was defined using the chi-square test, the Mann-
Whitney test and the Kruskal-Wallis test. A log rank test,
Kaplan-Meier curves and Cox multivariate regression
analysis were used in the survival analysis.
Ethics
The study design was approved by the Ethics committee
of Tampere University Hospital and the National Author-
ity for Medicolegal Affairs.
Results
Immunohistochemical staining of CA II, CA IX and CA
XII in tumour specimens is shown in Figure 1. CA II
showed two distinct staining patterns: the endothelium of
neovessels and the cytoplasm of MB/PNET cells. Of all
tumours, 49% (n = 18, 12 MBs/6 PNETs) stained posi-
tively for CA II in the tumour endothelium (32% strong,
11% moderate and 6% weak staining). Positive cytoplas-
mic CA II staining in tumour cells was found in 73% (n =
27, 20 MBs/7 PNETs) of the cases (11% strong, 38% mod-
erate and 24% weak staining).
CA IX and CA XII were less frequently expressed than
CA II in the tumour samples: 23% (n = 9, 8 MBs/1 PNET)
of the tumours were positive for CA IX (3% strong, 13%
moderate and 7% weak staining), and only 11% (n = 4, 3
MBs/1 PNET) of the tumours were positive for CA XII
(3% strong, 3% moderate and 5% weak staining). The CA
IX-specific antibody stained perinecrotic areas in most of
the tumours in which necrosis was visible. The CA XII
was more homogenously distributed than CA IX, consis-
tent with the results obtained previously in other
tumours such as ovarian tumours [42].
Since MBs/PNETs are rare tumours and the availability
of the specimens was limited to 39, the positively stained
tumours (scores 1-3) were pooled for most statistical
analyses, including the studies on patient survival. There
was no significant correlation in the co-expression of CA
II, IX and XII in the subgroups of MBs and PNETs nor
did we found a correlation in the group of all tumours
(chi-square test). We also compared CA II, IX and XII
expression with various clinical features and molecular
markers (Table 2). The expression of the CAs did not cor-
relate with proliferation (MIB-1), apoptosis (chi-square
and Mann-Whitney test) or expression of bcl-2, p53 or c-
erbB-2 in any of the groups except for the correlation
between c-erbB-2 and CA IX in PNETs (p = 0.047, chi-
square test). Interestingly, CA XII-positive staining corre-
lated with younger patient age (total material p < 0.001,
MBs p < 0.001, chi-square test, Table 2). Added to this,
C A  I X  p o s i t i v i t y  a s s o c i a t e d  w i t h  f e m a l e  g e n d e r  ( t o t a l
material p = 0.048, MBs p = 0.023, Table 2, chi-square
test). There was no significant difference in the expres-
sion of CAs between the primary and recurrent tumours
in any of the groups (chi-square test). Moreover, there
were no correlation between the tumour type (MBs/
PNETs) and CA intensity (chi-square test).
All 35 patients with primary MB/PNET were included
in the survival analysis (Figure 2). The patients with a CA
IX-positive MB/PNET had a worse prognosis than those
who had a CA IX-negative tumour (all tumours p = 0.041,
MBs p = 0.030, PNETs p = n.s.; log-rank test; Figure 2).
We also found a correlation between survival and CA XII
staining in patients with MB. The patients with CA XII-
positive tumours showed significantly worse prognosis (p
= 0.010, log-rank test). There was no significant differ-
ence in survival time between the histological subgroups
(p = 0.463, log-rank test). Of the prognostic indicators
used for MBs in the current WHO classification, (2007)
the following variables were included into the Cox multi-
variate survival analysis: patient age, MIB-1 proliferation
index, apoptosis index and expression of p53, c-erbB-2
and bcl-2. In addition, the histopathological group (MB
vs. supratentorial PNET), CA II, CA IX and CA XII were
used in the analysis. These variables were grouped as pre-
sented in Table 2. In the Cox analysis, only expression of
CA IX (odds ratio 4.31; 95% confidence interval (CI) 1.31
- 14.11; p = 0.016) and the apoptosis index (odds ratio
3.29; 95% CI 1.05 - 10.31, p = 0.041) were independent
prognostic factors. The expression of either CA II and
CA XII failed to show any significant association with
survival.
Discussion
In the present study, we demonstrate that several MBs
and supratentorial PNETs express the CA isozymes CA
II, CA IX and CA XII. According to the univariate sur-
vival analysis, expression of CA IX was found to be asso-
ciated with poor prognosis. Most importantly, the Cox
multivariate analysis, which included patient age, tumour
cell proliferation, apoptosis rate and several other molec-
u l a r  f a c t o r s ,  d e m o n s t r a t e d  t h a t  C A  I X  e x p r e s s i o n  a n d
apoptotic activity were the only independent prognostic
factors. The expression of CA XII in the tumour cells was
associated with patient age, as previously reported for the
expression of CA XII in patients with diffuse astrocy-
tomas [29]. These findings reflect the fact that patient age
is a significant factor that contributes to carcinogenesis
by several mechanisms and that tumour phenotypes are
different depending on the age of the patient.Nordfors et al. BMC Cancer 2010, 10:148
http://www.biomedcentral.com/1471-2407/10/148
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The expression of CA II, CA IX and CA XII in the nor-
mal nervous system has been investigated in several pre-
vious studies. The localization of CA II is well
documented in the normal human oligodendrocytes [43].
Based on our previous studies, CA IX is not present in
the normal human brain [16]. RT-PCR analysis has
shown very weak CA XII mRNA expression in the human
brain [29], and in mouse, immunohistochemical staining
has located CA XII to the choroid plexus [44].
CA IX has several functions in tumour progression. It
has been proposed to have a capacity to modulate E-cad-
herin-mediated cell adhesion, thus leading to a more
aggressive phenotype of malignant cells. In intercellular
j u n c t i o n s ,  C A  I X  m a y  b e  l i n k e d  t o  t h e  E - c a d h e r i n / β -
catenin complex, because CA IX co-immunoprecipitated
with β-catenin in cultured MDCK cells, a kidney cell line
[45]. It is also noteworthy that β-catenin is mutated in
some sporadic cases of MB [46]. The presence of CA IX
in the E-cadherin/β-catenin complex might contribute by
an unknown mechanism to increased invasion and
spread of tumour cells. Indeed, embryonal tumours differ
from other brain tumours by their tendency to metasta-
sise. In addition, our previous findings in diffusely infil-
trating astrocytomas are also in line with the suggested
role of CAs in the invasion process. Typically, CA IX-pos-
itive astrocytic tumours are highly invasive tumours with
an extremely poor prognosis [16]. A recent study by
Chiche et al. [47] provided clear evidence that both CA
IX and CA XII are functionally involved in tumour
growth. In vivo experiments showed that CA9  gene
silencing alone led to a 40% reduction in xenograft
tumour volume, and the silencing of both CA9 and CA12
resulted in an 85% reduction in tumour volume.
In this study, CA IX was found in the perinecrotic areas
of the tumours whenever necrosis was present. A similar
hypoxia-associated pattern of CA IX expression has been
Figure 1 Representative immunostaining of CA enzymes in MBs. Panel A shows no immunoreaction for CA IX, whereas the tumour in panel B is 
strongly positive. Panel C demonstrates CA XII-positive immunoreactivity in tumour cells. In panel D, CA II-positive immunostaining is confined to the 
endothelium of small blood vessels (arrows). All magnifications ×400.Nordfors et al. BMC Cancer 2010, 10:148
http://www.biomedcentral.com/1471-2407/10/148
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Table 2: Association of endothelial and cytoplasmic CA II, CA IX and CA XII immunostaining with clinicopathologic 
variables in medulloblastomas (MB) and primitive neuroectodermal tumours (PNET).
endothelial CA II positivity 
N
cytoplasmic CA II positivity 
N
CA IX positivity N CA XII positivity N
Primary tumors All MB PNET All MB PNET All MB PNET All MB PNET
3 3 2 763 3 2 763 5 2 873 4 2 77
Age
<  3  y e a r s 523532110 4 * 3 + 1
>  3  y e a r s 1 2 1 0 2 1 8 1 5 3761000
Gender
- f e m a l e 633 1 0 73 1 * * 0 + +  1101
- m a l e 1 1 92 1 3 1 1 2770330
Localization
-cerebellum 12 18 7 3
-cerebrum 5 5 1 1
Total material
MIB-1 3 6 2 883 6 2 883 7 2 983 6 2 88
- b e l o w  m e d i a n 963 1 3 1 0 3541110
- a b o v e  m e d i a n 963 1 3 94440211
Apoptosis 3 7 2 983 7 2 983 9 3 093 8 2 99
- b e l o w  m e d i a n 853 1 5 1 1 4550110
- a b o v e  m e d i a n 1 0 73 1 2 93431321
Bcl-2 3 7 2 983 7 2 983 9 3 093 8 2 99
- n e g a t i v e 642 1 3 94321101
- p o s i t i v e 1 2 84 1 4 1 1 3660330
P53 3 7 2 983 7 2 983 9 3 093 8 2 99
- n e g a t i v e1 5 61 2 3 91740300
- p o s i t i v e 3654 1 1 6241131
ErbB2 3 7 2 983 7 2 983 9 3 093 8 2 99
- n e g a t i v e 81 051 1 1 05 6 70 Ψ0 2 1
- p o s i t i v e 1 0 21 1 6 22311410
The total number of tumours analysed in each category is in bold.
* p < 0.001, chi-square test
** p = 0.048, chi-square test
+ p < 0.001, chi-square test
++ p = 0.023, chi-square test
Ψ p = 0.047, chi-square testNordfors et al. BMC Cancer 2010, 10:148
http://www.biomedcentral.com/1471-2407/10/148
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previously detected in astrocytic tumours [16]. Hypoxia
triggers architectural and phenotypic rearrangements of
tumour tissue, resulting in the development of necrotic
areas surrounded by zones of surviving hypoxic cells.
Importantly, these cells often become the most aggressive
tumour cells [48], in which CA IX expression is induced
by HIF1-α-regulated pathway [28]. Because necrosis is an
uncommon feature and is not considered to be a signifi-
cant prognostic factor in MBs, the induction of CA IX in
MBs/PNETs may also involve hypoxia-independent
mechanisms. Similarly, in previous studies on gliomas,
CA IX expression was seen in tumour cells located in
close proximity to the blood vessels [49], and it has been
shown that acidosis induces CA IX independently of peri-
cellular hypoxia in glioblastoma cell lines [31]. Based on
the previous studies, it has become clear that although
hypoxia is the key factor for CA IX induction, there may
be other important factors involved. Our text already
pointed out that tumor cell acidosis seems to contribute
to the expression level [31]. There are several studies
where CA IX expression has been correlated to pimo-
nidazole accumulation. The results have shown slightly
conflicting results, which may reflect to biological varia-
tion between different tumor types and dynamics of
tumor hypoxia. However, most results give support for
the idea that CA IX follows the pattern of pimonidazole
binding [50,51].
We have previously studied the expression of tumour-
associated CAs in other types of brain tumours. Endothe-
lial CA II was expressed in the neovessels of astrocytic
tumours, in which it was associated with poor prognosis
[17]. In addition, we have shown that both CA IX and CA
XII are independent prognostic factors in glial tumours
[16,29,30]. Based on these findings, CAs may play a cen-
tral role in the pathogenesis of malignant brain tumours
and may represent potential biomarkers for histopatho-
logical diagnosis of brain tumours. Although in the total
tumour material CA II and CA XII did not reach statisti-
cal significance in for use as prognostic indicators, CA II
had a similar trend to that of CA IX. Furthermore, CA XII
showed a significant correlation with survival in MBs. As
discussed above, these differences may be partly
explained by regulatory mechanisms. It has been also
shown that higher CA IX expression is associated with a
more favourable overall survival in some tumours, such
as in renal cell carcinoma (RCC) and in acute myeloid
leukemia (AML). In RCC the CA IX induction is associ-
ated with VHL-mutation and not with hypoxia as in brain
tumours [52]. In AML the association has been discussed
to be involved with immune system and T-cell response
[53]. Hypoxia-induced CA XII is less frequently
expressed in MBs/PNETs than in gliomas. Interestingly,
C A  I I  w a s ,  o n c e  a g a i n ,  f o u n d  i n  t h e  e n d o t h e l i u m  o f
neovessels and, thus, may play an important functional
role in tumour metabolism. In melanoma patients,
endothelial CA II represents a major target antigen in
dendritic cell therapy [19]. Further studies are, therefore,
clearly warranted to evaluate the role of CA II as a possi-
ble therapeutic target not only in melanoma but also in
other forms of cancer, including MBs/PNETs.
CA IX-specific inhibitors would represent ideal candi-
date molecules for cancer therapy, because CA IX is
highly expressed in several cancers while it shows a very
limited distribution in normal tissues [22]. Design of
isozyme-specific inhibitor has proved to be a great chal-
lenge, because the CA active site is quite similar in all
active alpha CA isoforms. The recently published crystal
structure of CA IX was certainly a major breakthrough
that will help to design novel inhibitors with higher speci-
ficity [54].
According to our results, apoptosis was another inde-
pendent prognostic factor in MBs/PNETs, although its
role seems to be controversial. On one hand, as we show
in this study, a higher apoptotic index is associated with
better prognosis [55]. On the other hand, previous stud-
ies in which the degree of apoptosis was categorised as
'focal', 'diffuse' or 'extensive' demonstrated a correlation
only between survival and focal apoptosis [6]. In addition,
it is known that bcl-2 is an inhibitor of apoptosis. In our
tissue samples, however, immunoreactivity for bcl-2 did
not correlate with better prognosis; although similar
results have been reported by others [56]. In our study,
apoptosis was an independent prognostic indicator of
MBs/PNETs. However, the study material was rather lim-
ited due to the fact that MBs and PNETs are rare
tumours, and studies will be needed to clarify the associa-
tion between apoptosis and survival. Added to this, the
time period in which the patients were treated, was rather
long and treatment protocols varied.
In the future, children diagnosed with MB/PNET will
be more accurately stratified based on a combination of
clinical variables and molecular profiles. Improved risk
stratification will enable individualised therapies, which
could be a combination of conventional treatment modal-
ities and novel, targeted therapeutic approaches. These
changes will hopefully result in improved survival with-
out a detriment in the quality of life. Several molecular
alterations have already been identified in MBs, many of
which appear to have prognostic significance.
Conclusions
Based on our results, CA IX seems to be a promising
prognostic marker that should be tested in a larger cohort
of MB/PNET patients. The expression of CA IX in some
MBs/PNETs suggests that it could be considered a poten-
tial therapeutic target, similar to other tumours includingNordfors et al. BMC Cancer 2010, 10:148
http://www.biomedcentral.com/1471-2407/10/148
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acute myeloid leukemia [53] and renal cancer [57]. Fur-
thermore, CA IX could be used for in vivo imaging and as
a target molecule for CA inhibitors [12,22].
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